Literature DB >> 33428652

Prevalence and correlates of metabolic syndrome and its components in adults with psychotic disorders in Eldoret, Kenya.

Edith Kwobah1, Nastassja Koen2,3,4, Ann Mwangi5, Lukoye Atwoli6, Dan J Stein2,3,4.   

Abstract

BACKGROUND: A high prevalence of metabolic syndrome and its components in patients with psychotic disorders may increase the risk for cardiovascular diseases. Unfortunately, relatively little work in this field has emerged from low-resourced contexts. This study investigated the prevalence, correlates, and treatment patterns of metabolic disorders in patients with psychotic disorders in Western Kenya.
METHODS: 300 patients with psychosis and 300 controls were recruited at Moi Teaching and Referral Hospital in Eldoret, Kenya. Data on demographic characteristics, weight, height, abdominal circumference, blood pressure, blood glucose, lipid profile, and treatments were collected. Categorical and continuous data were compared between the patient and control groups using Pearson's chi-squared tests and t-tests, respectively. Variables found to be significantly different between these groups were included in logistic regression models to determine potential predictors of metabolic syndrome.
RESULTS: Compared to controls, patients with psychosis were found to have a higher mean random blood glucose [5.23 vs 4.79, p = 0.003], higher body mass index [5.23 vs 4.79, p = 0.001], higher triglycerides [1.98 vs 1.56, p<0.001], larger waist circumference [89.23 vs 86.39, p = 0.009] and lower high density lipoprotein [1.22 vs 1.32, p<0.001]. The odds of developing metabolic syndrome were increased with age [OR = 1.05, CI: 1.02-1.07] and presence of a psychotic disorder [OR = 2.09 [CI 1.23-3.55]; and were reduced with female gender [OR 0.41, CI 0.25-0.67], among those who were never married [OR 0.52, CI 0.28-0.94] and among the widowed/separated/ divorced marital status [OR 0.38, CI 0.17-0.81]. While the majority of patients received treatment with olanzapine, there was no association between olanzapine use and metabolic syndrome and its components. More than half of the patients in this study sample were not receiving treatment for the various components of metabolic syndrome.
CONCLUSION: In the study setting of Eldoret, metabolic syndrome and its components were more prevalent among patients with psychotic disorders than in controls; and a clear treatment gap for these disorders was evident. There is a need for efforts to ensure adequate screening and treatment for these physical disorders in resource-limited settings.

Entities:  

Mesh:

Year:  2021        PMID: 33428652      PMCID: PMC7799838          DOI: 10.1371/journal.pone.0245086

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  53 in total

Review 1.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

2.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

3.  Metabolic changes associated with antipsychotic use.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

4.  Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: A cross-sectional study.

Authors:  Fahad D Alosaimi; Mohammed Abalhassan; Bandar Alhaddad; Nasser Alzain; Ebtihaj Fallata; Abdulhadi Alhabbad; Mohammed Z Alassiry
Journal:  Gen Hosp Psychiatry       Date:  2016-12-19       Impact factor: 3.238

Review 5.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

6.  Prevalence and correlates of diabetes mellitus and dyslipidaemia in a long-stay inpatient schizophrenia population in Singapore.

Authors:  Saleha Shafie; Siau Pheng Lee; Samantha Bee Cheng Ong; Peizhi Wang; Esmond Seow; Hui Lin Ong; Siow Ann Chong; Mythily Subramaniam
Journal:  Singapore Med J       Date:  2018-02-12       Impact factor: 1.858

7.  Cellular ionic alterations with age: relation to hypertension and diabetes.

Authors:  M Barbagallo; R K Gupta; L J Dominguez; L M Resnick
Journal:  J Am Geriatr Soc       Date:  2000-09       Impact factor: 5.562

8.  Prevalence, awareness, treatment and control of hypertension and their determinants: results from a national survey in Kenya.

Authors:  Shukri F Mohamed; Martin K Mutua; Richard Wamai; Frederick Wekesah; Tilahun Haregu; Pamela Juma; Loise Nyanjau; Catherine Kyobutungi; Elijah Ogola
Journal:  BMC Public Health       Date:  2018-11-07       Impact factor: 3.295

Review 9.  Sex differences in obesity, lipid metabolism, and inflammation-A role for the sex chromosomes?

Authors:  Temeka Zore; Maria Palafox; Karen Reue
Journal:  Mol Metab       Date:  2018-04-12       Impact factor: 7.422

Review 10.  Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes.

Authors:  Andre Pascal Kengne; Anastase Dzudie; Eugene Sobngwi
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  3 in total

1.  Triglyceride-Glucose Index for the Diagnosis of Metabolic Syndrome: A Cross-Sectional Study of 298,652 Individuals Receiving a Health Check-Up in China.

Authors:  Mingfei Jiang; Xiaoran Li; Huan Wu; Fan Su; Lei Cao; Xia Ren; Jian Hu; Grace Tatenda; Mingjia Cheng; Yufeng Wen
Journal:  Int J Endocrinol       Date:  2022-06-29       Impact factor: 2.803

2.  Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.

Authors:  Feyissa Challa; Tigist Getahun; Meron Sileshi; Zeleke Geto; Teshome S Kelkile; Sintayehu Gurmessa; Girmay Medhin; Miraf Mesfin; Melkam Alemayehu; Tigist Shumet; Anwar Mulugeta; Desalegn Bekele; Christina P C Borba; Claire E Oppenheim; David C Henderson; Abebaw Fekadu; Anna Carobene; Solomon Teferra
Journal:  BMC Psychiatry       Date:  2021-12-11       Impact factor: 3.630

3.  Prevalence and Factors Associated with Metabolic Syndrome in Patients at a Psychosocial Care Center: A Cross-Sectional Study.

Authors:  Dandara Almeida Reis da Silva; Ludmila Santana de Almeida; Livia Lugarinho Correa; Rodrigo Fernandes Weyll Pimentel; Antonio Marcos Tosoli Gomes; Ana Gabriela Travassos; Adriana Mattos Viana; Monique Magnavita Borba da Fonseca Cerqueira; Marcio Costa de Souza; Anderson Reis de Sousa; Paulo José Bastos Barbosa; Julita Maria Freitas Coelho; Lucelia Batista Neves Cunha Magalhães; Argemiro D'Oliveira Júnior; Jorge Lopes Cavalcante Neto; Charles Souza Santos; Luiz Carlos Moraes França; Juliana de Lima Brandão; Livia Fajin de Mello Dos Santos; Helena Ferraz Gomes; Ellen Marcia Peres; Thais Regis Aranha Rossi; Kairo Silvestre Meneses Damasceno; Millena Conceição das Mercês; Sandra Lúcia Fernandes; Eline de Almeida Soriano; Isolda Prado de Negreiros Nogueira Maduro; Tatiana Santos Brandão; Amanda Cardoso Menezes; Amália Ivine Costa Santana; Magno Conceição das Merces
Journal:  Int J Environ Res Public Health       Date:  2022-08-17       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.